AIM ImmunoTech(us:AIM)
0.1250
+2.21%
Updated on 2025-04-02
Open:0.1232
Close:0.1250
High:0.1347
Low:0.1205
Prev Close:0.1223
Volume:228266.00
Turnover:29252.94
Turnover Ratio:0.32%
Shares:72.29M
MarketCap:9.04M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1 | 1 | 0 | 0 | 0 | |
| 2024-03-31 | 40 | 4093840 | 8.15% | 2 | 8 | 15 |
| 2023-12-31 | 42 | 4153654 | 8.46% | 4 | 8 | 10 |
| 2023-09-30 | 40 | 4325946 | 8.87% | 6 | 6 | 11 |
| 2023-06-30 | 40 | 4488173 | 9.27% | 5 | 6 | 11 |
| 2023-03-31 | 39 | 4761245 | 9.84% | 1 | 6 | 13 |
| 2022-12-31 | 40 | 5362076 | 11.15% | 4 | 7 | 11 |
| 2022-09-30 | 38 | 5775537 | 12.01% | 2 | 4 | 11 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 1988704 | 3.96% | 0 | |
| 2024-03-31 | Blackrock Inc. | 698333 | 1.39% | -9473 | -1.34% |
| 2024-03-31 | Geode Capital Management, Llc | 351657 | 0.70% | 0 | |
| 2024-03-31 | Renaissance Technologies Llc | 220808 | 0.44% | 18800 | 9.31% |
| 2024-03-31 | State Street Corp | 173103 | 0.34% | 0 | |
| 2024-03-31 | Verition Fund Management Llc | 171000 | 0.34% | 9000 | 5.56% |
| 2024-03-31 | Bridgeway Capital Management, Llc | 108900 | 0.22% | 0 | |
| 2024-03-31 | Morgan Stanley | 85320 | 0.17% | 8002 | 10.35% |
| 2024-03-31 | Northern Trust Corp | 85206 | 0.17% | -360 | -0.42% |
| 2024-03-31 | Seacrest Wealth Management, Llc | 35063 | 0.07% | -2000 | -5.40% |
About
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Address:2117 SW Highway 484
Website:http://www.aimimmuno.com
Market Movers